267 related articles for article (PubMed ID: 24561662)
21. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
22. [Reversal for heparins and new anticoagulant treatments].
Kortchinsky T; Vigué B; Samama CM
Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
[TBL] [Abstract][Full Text] [Related]
23. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities].
Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S
Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105
[TBL] [Abstract][Full Text] [Related]
25. New data on the pharmacology of heparin and low molecular weight heparins.
Samama MM; Bara L; Gouin-Thibault I
Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
[TBL] [Abstract][Full Text] [Related]
26. Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins.
Xu Y; Chandarajoti K; Zhang X; Pagadala V; Dou W; Hoppensteadt DM; Sparkenbaugh EM; Cooley B; Daily S; Key NS; Severynse-Stevens D; Fareed J; Linhardt RJ; Pawlinski R; Liu J
Sci Transl Med; 2017 Sep; 9(406):. PubMed ID: 28878012
[TBL] [Abstract][Full Text] [Related]
27. Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A; Petitou M
Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
[TBL] [Abstract][Full Text] [Related]
28. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
29. In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
Falkon L; Garí M; Gich I; Fontcuberta J
Thromb Res; 1998 Jan; 89(2):79-83. PubMed ID: 9630311
[No Abstract] [Full Text] [Related]
30. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
31. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
32. Protamine reversal of low molecular weight heparin: clinically effective?
van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
[TBL] [Abstract][Full Text] [Related]
33. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
34. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
35. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy.
Béguin S; Welzel D; Al Dieri R; Hemker HC
Haemostasis; 1999; 29(2-3):170-8. PubMed ID: 10629396
[TBL] [Abstract][Full Text] [Related]
36. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
37. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
38. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.
Bianchini EP; Fazavana J; Picard V; Borgel D
Blood; 2011 Feb; 117(6):2054-60. PubMed ID: 21048158
[TBL] [Abstract][Full Text] [Related]
39. Caltrop-like Small-Molecule Antidotes That Neutralize Unfractionated Heparin and Low-Molecular-Weight Heparin In Vivo.
Zong Y; Lei Z; Yu SB; Zhang LY; Wu Y; Feng K; Qi QY; Liu Y; Zhu Y; Guo P; Zhou W; Zhang DW; Li ZT
J Med Chem; 2024 Mar; 67(5):3860-3873. PubMed ID: 38407934
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
Castro-López V; Harris LF; O'Donnell JS; Killard AJ
Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
